Clinical trial NCT03238196: Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
Official title: A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Metastatic Breast Cancer
Keywords: FGFR inhibitor
ER+ metastatic breast cancer
CDK4/6 inhibitor
Endocrine therapy
Lead sponsor: Vanderbilt-Ingram Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2017-08-03
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is an open-label, multi-institution, phase Ib trial that evaluates the safety and tolerability and preliminary anti-tumor activity of fulvestrant, palbociclib and erdafitinib in patients with ER+/HER2-/FGFR-amplified metastatic breast cancer.

Detailed description: Primary Objectives

To determine the safety and tolerability of fulvestrant, palbociclib and erdafitinib in patients with ER+/HER2-/FGFR-amplified MBC.

Secondary Objectives

* To determine the anti-tumor effect of fulvestrant, palbociclib and erdafitinib in patients with ER+/HER2-/FGFR-amplified MBC.
* Pharmacokinetic assessments of erdafitinib

Correlative Objectives

* To determine the therapeutic predictive role of FGFR1-4, CCND1-2, CDK4 and CDK6 amplifications, and RB1 and ESR1 mutations on clinical outcome
* To determine if the FGFR1 amplification levels is an early surrogate of response
* To determine if the cfDNA results at disease progression show new genomic alterations potentially associated with resistance to CDK4/6 and FGFR inhibition
* To determine pharmacodynamic biomarkers of FGFR inhibition

Eligibility criteria: Inclusion Criteria:

* Patients must be able to swallow and retain oral medication
* Patients must be ≥ 18 years of age
* Female patients of no childbearing potential must be post-menopausal. Postmenopausal female subjects should be defined prior to protocol enrollment by any of the following:
* Participants at least 60 years of age; OR
* Participants under 60 years of age and naturally (spontaneous, no alternative pathologic or physiological cause) amenorrhea for at least 12 months; OR
* Medical ovarian failure confirmed by follicle-stimulating hormone (FSH) and estradiol levels in the post menopausal range per local institutional normal range; OR
* Prior bilateral oophorectomy; OR
* Prior radiation castration with amenorrhea for at least 6 months; OR
* Treatment with a luteinizing hormone-releasing hormone (LH-RH) agonist (such as goserelin acetate or leuprolide acetate) is permitted for induction of ovarian suppression as long as it has been initiated at least 28 days prior to study enrollment
* Patients must have ECOG performance status 0 - 1
* Patients must have clinical stage IV or inoperable locoregional recurrent invasive mammary carcinoma that is:
* ER+ and/or PgR+ (≥ 1% positive stained cells) by immunohistochemistry (IHC)
* HER2-negative (by IHC or FISH, per ASCO guidelines)
* FGFR1 - 4 amplified
* Patients must have evaluable (may have either measurable or non-measurable) disease
* Patients must have available tissue for FGFR determination
* Patients must have had at least one line of therapy in the metastatic setting
* Current use of any of the drugs listed on the Cautionary Concomitant Med list has to be approved by the Study Chair
* Patients must have adequate hematologic, hepatic and renal function. All laboratory tests must be obtained within 2 weeks from study drug initiation. These include:
* ANC ≥ 1,500/mm3
* Platelet count ≥ 100,000/mm3
* HgB ≥ 9.0 g/dL
* Creatinine clearance ≥ 40 mL/min/1.73 m2
* SGOT, SGPT ≤ 2.5 x ULN if no liver metastasis present; SGOT, SGPT ≤ 4 x ULN if liver metastasis present
* Albumin ≥ 2.0 g/dL
* Total serum bilirubin ≤ 1.5 x ULN (≤ 3 x ULN or direct bilirubin ≤ 1.5 x ULN if known Gilbert's syndrome)
* Potassium within institutional normal limits
* Phosphorus ≤ institutional upper limit of normal

Exclusion Criteria:

* Prior use of an FGFR inhibitor
* More than 2 lines of chemotherapy in the metastatic setting. No limit on endocrine therapy lines. Prior exposure to CDK4/6 inhibitor acceptable.
* Radiation therapy ≤ 2 weeks prior to study entry. Patients who have received prior radiotherapy must have recovered from toxicity (≤ grade 1) induced by this treatment (except for alopecia)
* Prior cancer therapy (except for endocrine therapy) must have been discontinued for 1 week prior to initiation of study drugs
* Concurrent anti-cancer therapy other than the ones specified in the protocol is not permitted during study participation. Bisphosphonates or denosumab are allowed
* Major surgery within 4 weeks of enrollment
* Herbal preparations are not allowed throughout the study, and should be discontinued 14 days prior to initiation of study treatment
* Any corneal or retinal abnormality likely to increase the risk of eye toxicity, such as:
* Current corneal pathology such as keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation or ulceration
* Uncontrolled glaucoma despite standard of care therapy
* Diabetic retinopathy with macular edema
* Known active wet, age-related macular degeneration (AMD)
* Known central serous retinopathy (CSR) or retinal vascular occlusion (RVO)
* Uncontrolled intercurrent illness including, but not limited to:
* Malabsorption syndrome significantly affecting gastrointestinal function
* Ongoing or active infection requiring antibiotics/antivirals
* Impairment of lung function (COPD \> grade 2, lung conditions requiring oxygen therapy)
* Symptomatic congestive heart failure
* Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months
* Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment \[National Cancer Institute -Common Terminology Criteria for Adverse Events, Version 4.03, grade 3\]
* QTcF ≥ 480 msec on screening EKG
* Known history of clinically significant QT/QTc prolongation or Torsades de Pointes(TdP)
* ST depression or elevation of ≥ 1.5 mm in 2 or more leads
* Diarrhea of any cause ≥ CTCAE grade 2 that does not resolve within a few days when adequately treated with anti-diarrhea medications
* Psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance/pill diary
* Symptomatic brain metastases (patients with a history of brain metastases must be clinically stable for more than 4 weeks from completion of radiation treatment and be off steroids)
* Known history of chronic liver or chronic renal failure
* Poor wound healing capacity

Primary outcomes:
measure: Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)
timeFrame: From the time of randomization up to 4 weeks of treatment (cycle 1), for each patient
Secondary outcomes:
measure: Progression-free Survival
timeFrame: Imaging studies will be performed every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
measure: Overall Response Rate
timeFrame: Imaging studies will be performed every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
measure: Clinical Benefit Rate (CBR; Complete Response + Partial Response + Stable Disease Without Disease Progression at 6 Months)
timeFrame: From the time of randomization up to 6 months for each patient
measure: Pharmacokinetic Assessment of Erdafitinib - Area Under the Curve (AUC)
timeFrame: From the time of randomization up to 4 weeks of treatment for each patient
measure: Pharmacokinetic Assessment of Erdafitinib - Cmax (Maximum Plasma Concentration)
timeFrame: From the time of randomization up to 4 weeks of treatment for each patient
measure: Pharmacokinetic Assessment of Erdafitinib - Tmax
timeFrame: From the time of randomization up to 4 weeks of treatment for each patient
measure: Pharmacokinetic Assessment of Erdafitinib - CL/F
timeFrame: From the time of randomization up to 4 weeks of treatment for each patient
measure: Incidence of Treatment-Emergent Adverse Events [Tolerability]
timeFrame: From date of randomization until 28 days post treatment discontinuation from any cause, assessed up to 48 months
Other outcomes:
measure: Serial Measurements of Serum Phosphate, Calcium, Vitamin D, Parathyroid Hormone (PTH), FGF23, sFGFR2, sFGFR3, and sFGFR4
timeFrame: During the first 8 weeks of treatment (days 1, 8, 15, 22 of cycle 1 and days 1 and 15 of cycle 2)
measure: FGFR1 Amplification Levels by FISH and cfDNA
timeFrame: At study entry (baseline)
measure: Next Generation Sequencing
timeFrame: At study entry (baseline)
measure: Plasma Cell-free Deoxyribonucleic Acid (cfDNA)
timeFrame: At study entry (baseline), at 4 weeks, and at study discontinuation from disease progression (for each patient), assessed up to 48 months.
Locations:
city: Birmingham
country: United States
facility: University of Alabama
state: Alabama
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
city: Memphis
country: United States
facility: Baptist Memorial Hospital MEMPHIS
state: Tennessee
city: Nashville
country: United States
facility: Vanderbilt-Ingram Cancer Center
state: Tennessee
city: Dallas
country: United States
facility: University of Texas Southwestern Simmons Comprehensive Cancer Center
state: Texas
Study officials:
affiliation: Vanderbilt-Ingram Cancer Center
name: Brent Rexer, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: